

Name of Committee: National Center for Research Resources Special Emphasis Panel Exploratory Centers for Interdisciplinary Research (02).

Date: July 22–23, 2004.

Time: July 22, 2004, 8 a.m. to Adjournment.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Prabha L. Atreya, Scientific Review Administrator, Office of Scientific Review, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD 20892, (301) 496–8633, atreya@pr@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.371, Biomedical Technology; 93.389, Research Infrastructure; 93.306, 93.333, National Institutes of Health, HHS)

Dated: May 27, 2004.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04–12790 Filed 6–4–04; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; “Medication Discovery Using Rat Models of Relapse to Drug Self-Administration”.

Date: June 24, 2004.

Time: 10:30 a.m. to 1 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Eric Zatman, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse,

NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1438.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health, HHS)

Dated: May 27, 2004.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04–12791 Filed 6–4–04; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Behavioral & Cognitive Processes Related to Adolescent Drug Abuse (RFA DA04–009).

Date: June 2–3, 2004.

Time: 8:30 a.m. to 3 p.m.

Agenda: To review and evaluate grant applications.

Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Mark R. Green, PhD, Deputy Director, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, 45 MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1431.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Member Conflict A.

Date: June 8, 2004.

Time: 1 p.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Mark R. Green, PhD, Deputy Director, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1431.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Member Conflict B.

Date: June 9, 2004.

Time: 10:30 a.m. to 2 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Mark R. Green, PhD, Deputy Director, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1431.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; HIV/AIDS Prevention, Treatment, and Related Health Issues for Highly Vulnerable Youth (RFA DA04–012).

Date: June 29–30, 2004.

Time: 8:30 a.m. to 4 p.m.

Agenda: To review and evaluate grant applications.

Place: Residence Inn, Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Mark Swieter, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Boulevard, Suite 220, Bethesda, MD 20892–8401, (301) 435–1389.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Targeted Integrative Research in Drug Abuse and HIV/AIDS in Pregnancy.

Date: June 30, 2004.

Time: 9:30 a.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Health, 6101 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, 301–451–4530.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Centers Review Committee Meeting.

Date: July 12, 2004.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202.

Contact Person: Ria Liu, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 212, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1388.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; RFA for Animal Models of Adolescent Drug Abuse: Integrative Studies of Brain and Behavioral Development.

Date: July 14–15, 2004.

Time: 8:30 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: The Fairmont Washington, DC, 2401 M Street, NW., Washington, DC 20037.

Contact Person: Mark Swieter, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6101 Executive Boulevard, Suite 220, Bethesda, MD 20892–8401, (301) 435–1389.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Group Therapy for Individuals in Drug Abuse or Alcoholism Treatment.

Date: July 22–23, 2004.

Time: 9 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Radisson Barcello, 2121 P Street, NW., Washington, DC 20037.

Contact Person: Kesinee Nimit, MD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1432.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health, HHS)

Dated: May 27, 2004.

LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04–12792 Filed 6–4–04; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Center for Substance Abuse Prevention; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the Substance Abuse and Mental Health Services Administration (SAMHSA) Drug Testing Advisory Board to be held in June 2004.

On June 8, the Board will meet in open session from 8:30 a.m. to 11:30 a.m. The open session will include a Department of Health and Human Services drug testing program update, a presentation on the revisions to the “Mandatory Guidelines for Federal Workplace Drug Testing” published in the **Federal Register** on April 13, 2004 (69 FR 19644–19673), and a Department of Transportation drug testing program update. If anyone needs special accommodations for persons with disabilities, please notify the Contact listed below.

The Board will meet in closed session on June 8, from 11:30 a.m. to 4:30 p.m. to review and evaluate proprietary testing processes and procedures of drug testing laboratories certified to perform drug testing in accordance with the “Mandatory Guidelines for Federal Workplace Drug Testing Programs” (Mandatory Guidelines) published in the **Federal Register** (59 FR 29908–29931 on June 9, 1994), 63 FR 51118–51119 on September 30, 1997, and 63 FR 63483 on November 13, 1998). Public disclosure of information concerning proprietary laboratory testing processes would result in competitive harm to the laboratories and significantly impede the cooperation of laboratories in fully disclosing information to inspectors during laboratory inspections. The meeting must be conducted in closed session because disclosure of such proprietary laboratory information would significantly impede the Department’s ability to certify laboratories to meet the standards of Subpart C of the Mandatory Guidelines and is therefore protected by exemption 9(B) of section 552b of title 5 U.S.C.

The Board will meet in closed session on June 9, from 8:30 a.m. until noon to review and discuss new specimen adulteration methods by which persons subject to drug testing may subterfuge the drug test and the Department’s ability to detect them. This meeting must be conducted in closed session since disclosing information on such specimen adulteration methods will significantly frustrate the Department’s ability to assure accurate and reliable drug and specimen validity testing, and is therefore protected by exemption 9(B) of section 552b(c) of title 5 U.S.C.

A roster of the board members may be obtained from: Mrs. Giselle Hersh, Division of Workplace Programs, 5600 Fishers Lane, Rockwall II, Suite 815, Rockville, MD 20857, 301–443–6014 (voice). The transcript of the open session will be available on the following Web site <http://workplace.samhsa.gov>. Additional

information for this meeting may be obtained by contacting the individual listed below.

Committee: Substance Abuse and Mental Health Service Administration Drug Testing Advisory Board.

Meeting Date: June 8, 2004; 8:30 a.m.–4:30 p.m. June 9, 2004; 8:30 a.m.–Noon.

Place: Residence Inn by Marriott, 7335 Wisconsin Avenue, Bethesda, Maryland 20814.

Type: Open: June 8, 2004; 8:30 a.m.–11:30 a.m. Closed: June 8, 2004; 11:30 a.m.–4:30 p.m. Closed June 9, 2004; 8:30 a.m.–Noon.

Contact: Donna M. Bush, Ph.D., Executive Secretary, 301–443–6014 (voice) or 301–443–3031 (fax).

Dated: May 17, 2004.

Toian Vaughn,

Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 04–12737 Filed 6–4–04; 8:45 am]

BILLING CODE 4162–20–M

DEPARTMENT OF HOMELAND SECURITY

Science and Technology Directorate; Notice of Intent To Prepare an Environmental Impact Statement

AGENCY: Science and Technology Directorate, DHS.

ACTION: Notice of intent to prepare an Environmental Impact Statement for the National Biosecurity Analysis and Countermeasures Center Facility at Fort Detrick, Maryland.

SUMMARY: The Department of Homeland Security (DHS) announces its intent to prepare an Environmental Impact Statement (EIS) to evaluate the construction and operation by DHS of the proposed new National Biosecurity Analysis and Countermeasures Center (NBACC) facility, at Fort Detrick in Frederick, Maryland. This EIS is being prepared and considered in accordance with requirements of the National Environmental Policy Act (NEPA) of 1969, regulations of the President’s Council on Environmental Quality (40 CFR parts 1500–1508), and Army Regulation 200–2, Environmental Analysis of Army Actions (32 CFR 651), 29 March 2002. The U.S. Army, as owner of the site of the proposed NBACC facility, is a Cooperating Agency in the preparation of this EIS.

DATES: Pursuant to the National Environmental Policy Act, a Public Scoping meeting will be held on Tuesday, June 22, 2004, 7 p.m.

ADDRESSES: The meeting location is Frederick Community College, 7932